Equine Influenza Virus Infection (Equine Influenza)

Equine influenza is a highly contagious, acute viral respiratory disease of horses caused by infection with the equine influenza virus (EIV), an enveloped, negative-sense, single-stranded RNA virus belonging to the family Orthomyxoviridae, genus Influenzavirus A. The disease is characterized by sudden onset of pyrexia (up to 41.1°C or 106°F), a harsh dry cough, serous to mucopurulent nasal discharge, depression, anorexia, and variable degrees of lymphadenopathy. EIV primarily affects the upper and lower respiratory tract, causing tracheitis, bronchitis, and bronchiolitis, with potential secondary bacterial pneumonia. The virus is transmitted via aerosolized respiratory secretions and fomites, and outbreaks can spread rapidly among susceptible equine populations, particularly in training yards, racetracks, and show grounds. Equine influenza is a major cause of morbidity and economic loss in the equine industry, leading to interrupted training, canceled competitions, and prolonged convalescence. The disease is endemic in many parts of the world, with vaccination being a cornerstone of prevention. The clinical severity varies with the strain, host immunity, and secondary complications. The incubation period is typically 1-3 days, and viral shedding can occur for up to 7-10 days post-infection. The disease is often self-limiting in uncomplicated cases, but severe outbreaks can result in significant mortality, especially in donkeys, mules, and immunologically naïve foals.

The primary causative agent is the equine influenza virus (EIV), a type A influenza virus. Two main subtypes have been recognized: H7N7 (equine-1) and H3N8 (equine-2). The H7N7 subtype is considered extinct in the field, while H3N8 remains the predominant circulating subtype. The virus is further classified into two lineages: American and Eurasian, with the American lineage having diverged into Kentucky, Florida, and South American sub-lineages. The virus possesses two major surface glycoproteins: hemagglutinin (HA) and neuraminidase (NA), which are critical for viral attachment and release, respectively. Antigenic drift and shift lead to the emergence of new strains, necessitating regular updates to vaccines. The virus is enveloped and susceptible to heat, detergents, and disinfectants. Transmission occurs via inhalation of aerosolized droplets from coughing horses, direct contact with nasal secretions, or indirect contact via contaminated equipment, water, or handlers. The virus replicates in the respiratory epithelium, causing ciliary destruction and mucosal inflammation, which predisposes to secondary bacterial infections. The incubation period is short (1-3 days), and viral shedding peaks within 2-3 days of infection, often before clinical signs are apparent.

Equine influenza is a global disease affecting all breeds of horses, donkeys, and mules. The disease is endemic in many countries, with outbreaks occurring sporadically in populations with low vaccination coverage or when new strains emerge. Thoroughbred and Standardbred racehorses are at highest risk due to high population density, frequent movement, and intense training schedules. Young horses (1-5 years) are more susceptible due to waning maternal immunity and lack of prior exposure. The disease shows no sex predilection. Outbreaks are more common in the fall and winter months, likely due to increased indoor housing and ventilation issues. Morbidity rates can reach 60-100% in susceptible populations, while mortality is generally low (<1%) but can be higher in donkeys, mules, and immunocompromised foals. The economic impact is substantial, with costs related to veterinary care, lost training days, and cancellation of racing events. The 2007 Australian outbreak, which was traced to an imported horse, resulted in a national lockdown and estimated costs of over $1 billion AUD. Vaccination reduces clinical severity and viral shedding but does not prevent infection entirely. The disease can become endemic in unvaccinated populations, with periodic outbreaks driven by antigenic drift.

The pathogenesis of equine influenza begins with inhalation of aerosolized virus, which attaches to sialic acid receptors on ciliated respiratory epithelial cells via the hemagglutinin protein. The virus enters the cell, undergoes replication, and causes cell lysis and desquamation of the ciliated epithelium. This leads to loss of mucociliary clearance, accumulation of mucus, and inflammation. The virus spreads rapidly along the respiratory tract, causing tracheitis, bronchitis, and bronchiolitis. The inflammatory response involves infiltration of neutrophils and macrophages, release of cytokines (e.g., IL-6, TNF-α), and oxidative stress. The damage to the epithelial barrier allows secondary bacterial invasion, leading to bronchopneumonia. The cough reflex is triggered by irritation of the tracheal and bronchial mucosa. Systemic signs such as fever and depression are mediated by pyrogenic cytokines. In severe cases, viral pneumonia can occur, especially in foals, leading to interstitial pneumonia and respiratory distress. The virus does not cause viremia, but the systemic effects are due to the inflammatory response. Recovery depends on regeneration of the respiratory epithelium, which may take 2-3 weeks. Exercise during the recovery period can exacerbate the lesions and prolong the disease.

Intrinsic risk factors include age (young horses 1-5 years are more susceptible), breed (Thoroughbreds and Standardbreds are overrepresented due to management), and immune status (unvaccinated or incompletely vaccinated horses). Stress factors such as intense training, transportation, and weaning can increase susceptibility. Extrinsic factors include overcrowding, poor ventilation in stables, mixing of horses from different sources, and inadequate biosecurity measures. Seasonal factors (fall/winter) and climatic conditions that favor viral survival and aerosol transmission also play a role. Management practices such as frequent shows, sales, and racing events increase the risk of exposure. The use of shared water troughs, grooming equipment, and trailers can facilitate fomite transmission. Lack of quarantine for new arrivals is a significant risk factor for outbreaks.

The clinical signs of equine influenza typically appear 1-3 days after exposure. The hallmark sign is a sudden onset of a harsh, dry, non-productive cough that can persist for 2-3 weeks. Fever is often the first sign, with temperatures reaching 39.5-41.1°C (103-106°F), lasting 1-3 days. Nasal discharge is initially serous, becoming mucopurulent if secondary bacterial infection occurs. Other signs include depression, anorexia, lethargy, and enlarged submandibular lymph nodes. In severe cases, tachypnea, dyspnea, and abnormal lung sounds (crackles, wheezes) may be present, indicating pneumonia. Myositis and muscle stiffness can occur, leading to reluctance to move. In foals, the disease can be more severe, with high fever, pneumonia, and even death. The clinical course is typically 1-2 weeks, but the cough may persist for several weeks. Horses that are exercised during the acute phase may develop more severe disease and prolonged recovery.

Differential diagnoses for equine influenza include other respiratory infections such as equine herpesvirus (EHV-1 and EHV-4), equine viral arteritis (EVA), strangles (Streptococcus equi subsp. equi), and other bacterial pneumonias. EHV-1 and EHV-4 infections can cause similar respiratory signs but often present with neurological signs (EHV-1) or abortion. EVA is characterized by fever, limb edema, and conjunctivitis, and can cause abortion. Strangles presents with fever, nasal discharge, and abscessation of the lymph nodes, which is not typical of influenza. Other differentials include allergic respiratory disease (heaves), exercise-induced pulmonary hemorrhage (EIPH), and interstitial pneumonia. Diagnostic differentiation relies on virus isolation, PCR, and serology. A history of sudden onset, high fever, and rapid spread among horses strongly suggests influenza.

The diagnostic approach for equine influenza begins with a thorough history and physical examination. If influenza is suspected, the following steps are recommended: 1) Collect nasopharyngeal swabs or tracheal washes for virus detection using RT-PCR or virus isolation. Samples should be taken within 3-5 days of onset of fever. 2) Perform serology on paired serum samples (acute and convalescent, 2-3 weeks apart) to demonstrate a 4-fold rise in antibody titers using hemagglutination inhibition (HI) or single radial hemolysis (SRH) tests. 3) Complete blood count (CBC) may show leukopenia and lymphopenia in the acute phase. 4) Thoracic auscultation and ultrasonography may reveal signs of pneumonia. 5) If secondary bacterial infection is suspected, tracheal wash or bronchoalveolar lavage (BAL) for cytology and culture is indicated. 6) In outbreak situations, rapid point-of-care tests (e.g., lateral flow antigen tests) can provide immediate results, but RT-PCR is the gold standard. 7) Rule out other respiratory pathogens via multiplex PCR panels. 8) Monitor for complications such as pneumonia or myositis with appropriate imaging (thoracic radiography) and bloodwork (muscle enzymes).

In uncomplicated equine influenza, the CBC may show mild leukopenia and lymphopenia in the early stages, followed by neutrophilia if secondary bacterial infection occurs. Fibrinogen and serum amyloid A (SAA) may be elevated, indicating inflammation. Blood gas analysis may reveal hypoxemia in cases of severe pneumonia. If myositis is present, serum creatine kinase (CK) and aspartate aminotransferase (AST) may be elevated. Peritoneal fluid analysis is not typically performed unless there is a suspicion of abdominal involvement, which is rare. In cases of secondary bacterial pneumonia, tracheal wash cytology will show degenerative neutrophils and intracellular bacteria, and culture will identify the causative organism. Serology is essential for diagnosis and surveillance, with a 4-fold rise in HI or SRH titers between acute and convalescent samples confirming infection.

Imaging modalities are primarily used to assess the lower respiratory tract for complications. Thoracic radiography may reveal interstitial or alveolar patterns in cases of viral or secondary bacterial pneumonia. Ultrasonography of the thorax can detect pleural effusion, lung consolidation, and abscesses. Endoscopy of the upper airways can reveal tracheitis, with hyperemia, edema, and excessive mucus. Bronchoalveolar lavage (BAL) cytology may show increased neutrophils and evidence of bacterial infection. In severe cases, computed tomography (CT) can provide detailed images of the lungs, but it is rarely necessary. Imaging is not typically used for diagnosis of uncomplicated influenza but is valuable for assessing complications.

Cytological examination of tracheal wash or BAL samples is useful for identifying secondary bacterial infections. In uncomplicated viral infections, cytology may show increased mucus, ciliated epithelial cells, and a mixed inflammatory infiltrate with lymphocytes and macrophages. In secondary bacterial pneumonia, there is a marked neutrophilic inflammation with degenerative neutrophils and intracellular bacteria. Histopathology of lung tissue from fatal cases shows necrotizing bronchitis and bronchiolitis, with desquamation of the epithelium, alveolar edema, and inflammatory cell infiltration. Immunohistochemistry can confirm the presence of viral antigen.

Treatment of equine influenza is primarily supportive, as there is no specific antiviral therapy approved for horses. The main goals are to reduce fever, maintain hydration, prevent secondary bacterial infections, and provide rest. Non-steroidal anti-inflammatory drugs (NSAIDs) such as flunixin meglumine (1.1 mg/kg IV or PO q12-24h) or phenylbutazone (2.2-4.4 mg/kg PO q12-24h) are used to control fever and inflammation. Horses should be rested for at least 1 week per day of fever, with a minimum of 2-3 weeks of rest to allow respiratory epithelium to recover. Antibiotics are indicated if secondary bacterial pneumonia is suspected or confirmed; common choices include penicillin G (22,000 IU/kg IV q6h) and gentamicin (6.6 mg/kg IV q24h) or trimethoprim-sulfamethoxazole (30 mg/kg PO q12h). Cough suppressants are generally not recommended, as coughing helps clear secretions. In severe cases, oxygen supplementation and nebulization with bronchodilators (e.g., albuterol) may be beneficial. Fluid therapy may be necessary for dehydrated horses. Strict rest and isolation are critical to prevent spread. Vaccination is the primary preventive measure, with inactivated or modified-live vaccines available; annual boosters are recommended, with more frequent administration for high-risk horses.

The prognosis for uncomplicated equine influenza is excellent, with most horses recovering fully within 2-3 weeks. However, the prognosis is guarded in cases with secondary bacterial pneumonia, severe viral pneumonia, or in immunocompromised animals. Mortality is low (<1%) but can be higher in donkeys, mules, and foals. Return to athletic performance is generally good, but horses may require an extended rest period to avoid complications such as chronic cough or exercise intolerance. Negative prognostic indicators include persistent fever, dyspnea, and evidence of pneumonia on imaging. Early diagnosis and appropriate management improve the outcome.

Follow-up care for equine influenza includes monitoring temperature, respiratory rate, and appetite daily. Horses should be rested for at least 1 week per day of fever, with a minimum of 2-3 weeks of rest. Recheck examination, including thoracic auscultation and possibly thoracic radiography, is recommended 2-4 weeks after clinical resolution to ensure no residual lung pathology. Gradual return to exercise is advised, starting with hand-walking and progressing to trotting and cantering over 2-4 weeks. Vaccination should be updated according to the recommended schedule. In outbreak situations, quarantine of affected horses and biosecurity measures should be maintained for at least 2 weeks after the last case.

Clinical pearls: 1) A sudden onset of a harsh cough and high fever in a group of horses is highly suggestive of equine influenza. 2) Early diagnosis via RT-PCR is crucial for outbreak control. 3) Rest is the most important treatment; exercise during the acute phase can lead to severe complications. 4) Vaccination is effective in reducing clinical signs but does not prevent infection. Pitfalls: 1) Misdiagnosis as a bacterial infection leading to unnecessary antibiotic use. 2) Failure to isolate affected horses, leading to rapid spread. 3) Returning horses to work too soon, resulting in prolonged cough or pneumonia. 4) Overlooking secondary bacterial infections, which can be fatal.

Current drug protocols for equine influenza are primarily supportive. Flunixin meglumine: 1.1 mg/kg IV or PO q12-24h for fever and inflammation. Phenylbutazone: 2.2-4.4 mg/kg PO q12-24h (max 4.4 mg/kg/day). For secondary bacterial infections, penicillin G (22,000 IU/kg IV q6h) and gentamicin (6.6 mg/kg IV q24h) are commonly used; alternatively, trimethoprim-sulfamethoxazole (30 mg/kg PO q12h) or doxycycline (10 mg/kg PO q12h) may be used. Antiviral drugs such as oseltamivir are not approved for horses and have limited efficacy. Fluid therapy with balanced electrolyte solutions (e.g., lactated Ringer's solution) at maintenance rates (50 ml/kg/day) is indicated if dehydrated. Bronchodilators such as clenbuterol (0.8-3.2 mcg/kg PO q12h) may be used for bronchospasm. Mucolytics like N-acetylcysteine (10 mg/kg PO q12h) can help clear secretions. All dosages should be adjusted based on clinical response and renal function.

Landmark studies on equine influenza include the 2007 Australian outbreak investigation, which highlighted the importance of biosecurity and vaccination. Research by Cullinane et al. (2010) demonstrated the efficacy of vaccination in reducing clinical signs and viral shedding. A study by Daly et al. (2004) showed that the Florida sub-lineage of H3N8 is more virulent and has replaced older strains. The ACVIM consensus statement on equine influenza (2015) recommends annual vaccination for all horses, with more frequent boosters for high-risk populations. Studies on antiviral therapy are limited, but oseltamivir has shown some efficacy in experimental models. The use of rest and NSAIDs is well-supported by clinical experience. Overall, the evidence supports vaccination as the most effective preventive measure, and early diagnosis with RT-PCR is crucial for outbreak control.